NCT04542824Active, not recruitingPhase 1/2
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A Phase 1/2, Open-Label, Dose-Escalation Trial With Expansion Cohorts
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
The trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab (EPKINLY™) in Japanese participants with relapsed, progressive or refractory B-cell lymphomas and Japanese participants with B-cell lymphomas that have achieved partial response (PR) or complete response (CR) following prior standard of care (SOC). The trial consists of two parts: Part 1, dose escalation (phase 1), and Part 2, expansion (phase 2). The purpose of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended Phase-2 dose (RP2D), as well as to establish the safety profile of epcoritamab in Japanese participants with relapsed, progressive or refractory B-cell lymphoma and Japanese participants with B-cell lymphomas that have achieved PR or CR. In the expansion part, additional participants will be treated with epcoritamab, at the RP2D and the purpose is to further explore and determine the safety and efficacy of epcoritamab. Part 2 of the trial will be initiated once the RP2D has been determined in Part 1. In Part 2, epcoritamab is investigated as a monotherapy and in combination with other SOC agents.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 78 (actual)
- First submitted
- 25 Aug 2020
- Start date
- 20 Aug 2020
- Primary completion date
- Sept 2027
- Lead sponsor
- Genmab
- NCT number
- NCT04542824
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 78
- From 20 Aug 2020 to the primary completion date, Sept 2027
- 15 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindication to any of the individual drugs of the R-CHOP regimen
- Arm 4:
- Contraindication to any of the individual drugs of the GemOx regimen
- Arm 5:
Other
- Arm 2:
- FL Grade 3b
- Histologic evidence of transformation to an aggressive lymphoma
- Contraindication to rituximab or lenalidomide
- Unwilling or unable to take aspirin prophylaxis or prophylactic anticoagulant as clinically indicated
- Arm 3:
- FL Grade 3b
- Histologic evidence of transformation to an aggressive lymphoma
Criteria the registry did not label
- Main Inclusion Criteria:
- Must be at least 20 years of age, inclusive
- Japanese participants
- CD20 positivity at representative tumor biopsy
- Part 1:
- Diffuse large B-cell lymphoma (de novo or histologically transformed)
- High-grade B-cell lymphoma
- Primary mediastinal large B-cell lymphoma
- Follicular lymphoma
- Marginal zone lymphoma (nodal, extranodal of mucosa-associated lymphoid tissue, or splenic)
- Small lymphocytic lymphoma
- Part 2 :
- Arm 1:
- Diffuse large B-cell lymphoma (de novo or histologically transformed)
- Follicular lymphoma grade 1-3A
- Relapsed or refractory disease and previously treated with at least 2 lines of systemic antineoplastic therapy including at least 1 anti-CD20 monoclonal antibody (mAb)-containing therapy.
- Measurable disease by computed tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography (PET)-CT scan
- Arm 2:
- R/R FL grade 1, 2 or 3a, stage II, III, or IV, without evidence of transformation.
- Previously treated with at least 1 prior anti-neoplastic agent, including anti-CD20 antibody
- Must have a need for treatment initiation based on symptoms and/or disease burden (Groupe d'Etude des Lymphomes Folliculaires \[GELF\] criteria)
- Eligible to receive R2 per investigator determination
- Arm 3:
- One of following confirmed histologies (de novo or histologically transformed from FL or nodal marginal zone lymphoma) :
- o DLBCL, not otherwise specified (NOS)
- "Double-hit" or "triple-hit" DLBCL
- FL Grade 3B.
- T-cell/histiocyte rich large B-cell lymphoma (LBCL)
- International Prognostic Index (IPI) score ≥3
- No prior therapy for DLBCL or FL grade 3B (G3B) other than nodal biopsy, corticosteroids, or palliative radiotherapy.
- Eligible to receive R-CHOP per investigator determination
- Arm 4:
- One of following confirmed histologies (de novo or histologically transformed from FL or nodal marginal zone lymphoma) including:
- o DLBCL, NOS.
- o "Double-hit" or "triple-hit" DLBCL
- FL Grade 3B.
- T-cell/histiocyte rich LBCL
- Relapsed or refractory to at least one prior therapy including at least one prior anti-CD20 antibody.
- Either failed prior autologous hematopoietic stem cell transplantation (ASCT), or ineligible for autologous hematopoietic stem-cell transplantation (HSCT)
- Eligible to receive GemOx per investigator determination
- Arm 5:
- History of histologically confirmed CD20+ FL Grade 1-3a without evidence of transformation.
- In CR or PR per Lugano criteria following first-line or second-line treatment with SOC regimen, including anti-CD20 antibody, and last dose of SOC within 6 months prior to enrollment
- Main Exclusion Criteria:
- Primary central nervous system (CNS) lymphoma or CNS involvement by lymphoma at screening
- Participants not eligible for high dose therapy with autologous hematopoietic stem cell transplantation due to personal choice, social issues, or similar
- Known clinically significant cardiac disease
- Chronic ongoing infectious diseases requiring treatment (excluding prophylactic treatment)
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (15)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NHO Nagoya Medical Center Coordinator of this site? Confirm its status | Aichi | Japan | Unknown status |
| Aichi Cancer Center Hospital Coordinator of this site? Confirm its status | Aichi | Japan | Unknown status |
| National Cancer Center Hospital East Coordinator of this site? Confirm its status | Chiba | Japan | Unknown status |
| Matsuyama Red Cross Hospital Coordinator of this site? Confirm its status | Ehime | Japan | Unknown status |
| National Hospital Organization Kyushu Cancer Center Coordinator of this site? Confirm its status | Fukuoka | Japan | Unknown status |
| Fukushima Medical University Hospital Coordinator of this site? Confirm its status | Fukushima | Japan | Unknown status |
| Kagoshima University Hospital Coordinator of this site? Confirm its status | Kagoshima | Japan | Unknown status |
| Kyoto University Hospital Coordinator of this site? Confirm its status | Kyoto | Japan | Unknown status |
| Osaka University Hospital Coordinator of this site? Confirm its status | Osaka | Japan | Unknown status |
| Kindai University Hospital Coordinator of this site? Confirm its status | Osaka | Japan | Unknown status |
| Tohoku University Hoaspital Coordinator of this site? Confirm its status | Sendai | Japan | Unknown status |
| Tokyo Medical University Hospital Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
| National Cancer Center Hospital Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
| Cancer Institute Hospital of JFCR Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
| Yamagata University Hospital Coordinator of this site? Confirm its status | Yamagata | Japan | Unknown status |
Related publications
- Exposure-Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma.Clin Pharmacokinet · 2026 · PMID 42541678
- Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.Clin Pharmacol Ther · 2026 · PMID 42411504
This page is information, not medical advice. Discuss any trial with your doctor.